Kancera receives patent grant in US for the drug candidate KAND145

Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.

Read More

Kancera provides operational update in connection with the interim report for the first quarter of 2022

This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.

Read More

Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), 556806-8851

First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022·        Net sales amounted to SEK 0 million (SEK 0.0 million).·        R&D costs amounted to SEK 10,6 million (8,2 million).·        Operating...

Read More

Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), 556806-8851

The year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...

Read More

Kancera appoints Peter Selin as Executive Vice President Corporate Development


Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.

Read More